Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;33(7):1140-1144.
doi: 10.1038/s41433-019-0388-0. Epub 2019 Mar 4.

Systemic oxidative stress in non-arteritic anterior ischemic optic neuropathy

Serife Birer  1 , Hatice Arda  2 , Deniz Kilic  3 , Gulden Baskol  4
Affiliations

Systemic oxidative stress in non-arteritic anterior ischemic optic neuropathy

Serife Birer et al. Eye (Lond). 2019 Jul.

Abstract

Purpose: To investigate whether the serum total oxidant status (TOS), total antioxidant status (TAS), advanced oxidation protein products (AOPP), and thiol parameters could play a role in the pathogenesis of non-arteritic anterior ischemic optic neuropathy (NA-AION).

Methods: In this study, 18 newly diagnosed NA-AION patients and 17 healthy subjects (control group) were included. Serum plasma TOS and TAS, AOPP, and thiol parameters were measured by spectrophotometric method and the results were compared.

Results: Mean age of the patients and the controls were 60.8 ± 8.4 and 61.9 ± 9.4 years, respectively (p = 0.729). There were no significant differences between the patients and the control group with regard to the values of TAS, TOS, AOPP, and thiol (p = 0.869, p = 0.863, p = 0.040, p = 0.314; respectively). There was a positive correlation between TOS and thiol (p = 0.002, r = 0.681).

Conclusion: We found no significant relationship between systemic oxidative parameters and NA-AION. However, this study should be accepted as a pilot investigation and needs to be validated.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Advanced oxidation protein productvalues
See this image and copyright information in PMC

References

    1. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol. 2004;17:27–35. doi: 10.1097/00019052-200402000-00006. - DOI - PubMed
    1. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103–7. doi: 10.1016/S0002-9394(14)70999-7. - DOI - PubMed
    1. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14:38–44. doi: 10.1097/00041327-199403000-00011. - DOI - PubMed
    1. Buono LM, Foroozan R, Sergott RC, Savino PJ. Nonarteritic anterior ischemic optic neuropathy. Curr Opin Ophthalmol. 2002;13:357–61. doi: 10.1097/00055735-200212000-00003. - DOI - PubMed
    1. Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002;134:317–28. doi: 10.1016/S0002-9394(02)01639-2. - DOI - PubMed

Substances